Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-134-VI | Cediranib | VEGFR/cKIT | RTK | 4.2103 | -0.9999 | 0.0977 | 0.0979 | 5.0000 | 5.2449 | 0.99321 |
MDA-MB-134-VI | Ceritinib | ALK | RTK | 0.13159 | -0.9992 | 0.6654 | 0.1723 | 0.9173 | 0.43587 | 0.98922 |
MDA-MB-134-VI | Abemaciclib | CDK4/6 | Cell cycle | Inf | -0.9986 | 0.5722 | 0.0709 | 0.0000 | Inf | 0.086291 |
MDA-MB-361 | Ceritinib | ALK | RTK | 0.26636 | -0.9910 | 0.5462 | 0.1443 | 0.8263 | 1.0067 | 0.97236 |
MDA-MB-361 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0017737 | -0.9902 | 1.4103 | 0.4329 | 0.6207 | 0.010237 | 0.9975 |
MDA-MB-361 | Cediranib | VEGFR/cKIT | RTK | 2.2171 | -0.9803 | 0.2895 | 0.1040 | 2.2939 | 3.5791 | 0.96048 |
MDA-MB-361 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0050713 | -0.9642 | 0.8689 | 0.2561 | 0.9911 | 0.014575 | 0.99687 |
MDA-MB-361 | Buparlisib | pan PI3K | PI3K/mTOR | 0.21797 | -0.9584 | 0.6114 | 0.1763 | 0.9709 | 0.67584 | 0.99384 |
HCC1500 | Ceritinib | ALK | RTK | 1.4068 | -0.9535 | 0.2988 | 0.1206 | 1.5745 | 2.8266 | 0.97255 |
MDA-MB-134-VI | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0051713 | -0.9461 | 0.8935 | 0.2182 | 1.1423 | 0.01301 | 0.99597 |
MDA-MB-134-VI | Doxorubicin | Chemo | Chemotherapy | 0.0033105 | -0.9458 | 1.1481 | 0.2491 | 0.9132 | 0.010163 | 0.97259 |
PDX1328 | Ceritinib | ALK | RTK | 0.25503 | -0.9426 | 0.5536 | 0.1190 | 0.8974 | 0.86749 | 0.9878 |
MDA-MB-361 | Vorinostat | HDAC | Misc | 0.76224 | -0.9392 | 0.4607 | 0.1761 | 2.2187 | 1.2401 | 0.99784 |
MDA-MB-361 | Pictilisib | pan PI3K | PI3K/mTOR | 0.079201 | -0.9375 | 0.7161 | 0.1619 | 0.6291 | 0.45409 | 0.98391 |
MDA-MB-157 | Ceritinib | ALK | RTK | 0.48405 | -0.9264 | 0.4600 | 0.1138 | 0.9467 | 1.5449 | 0.97503 |
PDX1328 | Topotecan | Topo I | Chemotherapy | 0.0059222 | -0.9128 | 1.0720 | 0.1509 | 0.4616 | 0.063175 | 0.94441 |
MDA-MB-157 | Dinaciclib | pan CDK | Cell cycle | 0.017724 | -0.9106 | 0.7675 | 0.3195 | 3.8857 | 0.023072 | 0.99901 |
HCC70 | Dinaciclib | pan CDK | Cell cycle | 0.01286 | -0.9093 | 0.8338 | 0.3254 | 5.0000 | 0.015807 | 0.9991 |
PDX1328 | ABT-737 | Bcl2/XL | Misc | 1.0279 | -0.8967 | 0.3548 | 0.1542 | 1.3255 | 2.3546 | 0.97784 |
MDA-MB-134-VI | Topotecan | Topo I | Chemotherapy | 0.0099907 | -0.8909 | 1.0405 | 0.1644 | 0.5440 | 0.071904 | 0.95834 |
MDA-MB-361 | Luminespib | HSP90 | Misc | 0.0071417 | -0.8855 | 0.9781 | 0.3455 | 4.9987 | 0.0087421 | 0.9995 |
MDA-MB-134-VI | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0033793 | -0.8853 | 1.2003 | 0.2512 | 1.2527 | 0.007425 | 0.99747 |
HCC70 | Ceritinib | ALK | RTK | 3.1923 | -0.8808 | 0.1379 | 0.0703 | 5.0000 | 3.9213 | 0.99483 |
MDA-MB-134-VI | ABT-737 | Bcl2/XL | Misc | 1.7727 | -0.8735 | 0.2629 | 0.1112 | 1.9770 | 3.09 | 0.99496 |
HCC1428 | Ceritinib | ALK | RTK | 1.2414 | -0.8673 | 0.3014 | 0.1288 | 1.6178 | 2.4481 | 0.99584 |